Ovid Therapeutics Inc.
OVID- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636651
No open-market purchases or sales by Ovid Therapeutics Inc. insiders were filed in the last 90 days; 130 institutions reported holding it in 13F filings for Q2 2026, worth $395.5M in total; no superinvestor holds it.
Holders of 5% or more of OVID
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Ovid Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 13G/A | 12.30%8.78M shares | – | Dec 9, 20251 filing | Dec 9, 2025 | SEC |
| Janus Henderson Group PLC | 13G | 9.99%7.11M shares | New | Dec 8, 20251 filing | Dec 8, 2025 | SEC |
| Ra Capital Management, L.P. | 13G | 9.90%13.3M shares | New | Dec 18, 20251 filing | Dec 18, 2025 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 9.00%12.1M shares | 0.00 ppfrom 9.00% | Dec 18, 20252 filings | Jan 29, 2026 | SEC |
| ADAR1 Capital Management, LLC | 13G | 6.90%9.28M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Federated Hermes, Inc. | 13G | 5.94%7.74M shares | New | Jan 8, 20261 filing | Jan 8, 2026 | SEC |
| Point72 Asset Management, L.P. | 13G | 5.10%6.73M shares | New | Jan 5, 20261 filing | Jan 5, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Ovid Therapeutics Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20268:17 PM ET | ADAR1 Capital Management, LLCand 2 others | 13G | 6.90%9.28M shares | New | Dec 31, 2025 | SEC |
| Jan 29, 20267:57 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G/A | 9.00%12.1M shares | 0.00 ppfrom 9.00% | Jan 22, 2026 | SEC |
| Jan 8, 202611:56 AM ET | Federated Hermes, Inc.and 4 others | 13G | 5.94%7.74M shares | New | Dec 31, 2025 | SEC |
| Jan 5, 20264:12 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.10%6.73M shares | New | Jan 2, 2026 | SEC |
| Dec 18, 20256:07 PM ET | Ra Capital Management, L.P.and 3 others | 13G | 9.90%13.3M shares | New | Dec 11, 2025 | SEC |
| Dec 18, 20254:06 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G | 9.00%12.1M shares | New | Dec 11, 2025 | SEC |
| Dec 9, 20259:02 PM ET | Takeda Pharmaceutical Co Ltdand 1 other | 13G/A | 12.30%8.78M shares | – | Dec 8, 2025 | SEC |
| Dec 8, 202511:45 AM ET | Janus Henderson Group PLC | 13G | 9.99%7.11M shares | New | Nov 28, 2025 | SEC |
| Jul 21, 20256:36 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 0.00%0 shares | –Below 5% | Jul 17, 2025 | SEC |
| Jul 17, 20258:12 PM ET | BlackRock, Inc. | 13G/A | 1.90%1.37M shares | –Below 5% | Jun 30, 2025 | SEC |
| Jul 9, 20254:08 PM ET | Rubric Capital Management LPand 1 other | 13G/A | 0.67%478.5K shares | –Below 5% | Jun 30, 2025 | SEC |
| Feb 14, 20255:41 PM ET | Madison Avenue Partners, LPand 5 others | 13G/A | 4.00%2.85M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Ovid Therapeutics Inc. shares.
No Form 144 notices for Ovid Therapeutics Inc. are on file.